CagriSema phase 2 combination paper is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
Journal club: the CagriSema phase 2 combination paper — a second dataset
CagriSema phase 2 combination paper is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
This is the first time the answer has come with its own limits attached. Appreciated.
This is the sort of exchange that makes the archive worth searching.
That is a fair summary of where the discussion has got to.
The summary that goes to the digest should say what the paper establishes, what it does not, and one thing the group could not settle. Three paragraphs, no more.
The literature is thinner on this than the confidence in the thread implies.
Suggest the next paper at the end of the session rather than by message afterwards. The room has just worked out what it wants to know next.
If that is already documented somewhere, ignore me and link it.
Sessions run better when the paper is circulated with three specific questions attached. Open-ended reading produces an open-ended discussion.
Read the full topic (80 posts)
This topic was referenced in
- Journal club: STEP 3 and the intensive behavioural therapy floor — does this still hold?Evidence › Journal club · 2 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Journal club: STEP 3 and the intensive behavioural therapy floor
Posting this under the heading it deserves: Journal club: STEP 3 and the intensive behavioural therapy floor Everything below is what sits behind that. Two things I would like separated before anyone answers…
|
+6 | 10 | 13k | 28d |
|
Journal club: indirect comparison between two programmes, defended and attacked
Journal club: indirect comparison between two programmes, defended and attacked Writing it up because I had to work it out twice and would rather nobody else did. Trying to work out what would count as…
|
+122 | 131 | 5.2k | just now |
|
Journal club: is percentage weight change the right endpoint?
Journal club: is percentage weight change the right endpoint? I have a specific reason for asking rather than idle curiosity, and the context is below. Bringing a claim rather than a paper, because the claim…
|
+116 | 120 | 23k | 3mo |
|
Follow-up: Journal club: orforglipron phase 2 and the non-peptide question
Posting this under the heading it deserves: Journal club: orforglipron phase 2 and the non-peptide question Everything below is what sits behind that. A follow-up question about orforglipron phase 2 that I…
|
+80 | 91 | 10k | 11mo |
|
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
+61 | 65 | 2k | 13mo |
Related topics — sharing the tags journal club, estimand, effect size
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Subgroup analyses: pre-specified versus discovered — a second dataset
On the subject in the title: Subgroup analyses: pre-specified versus discovered — a second dataset Working notes rather than a conclusion. Posting a small dataset on Subgroup analyses. It is mine, it is…
|
+71 | 79 | 906 | 3mo |
|
Criticising the method without criticising the authors
Criticising the method without criticising the authors Writing it up because I had to work it out twice and would rather nobody else did. I was wrong about criticising the method without criticising in a…
|
+55 | 61 | 60k | 15mo |
|
Journal club: SELECT, absolute risk, and how it was reported
Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…
|
2 | 52k | 1mo | |
|
What we do not know about retatrutide, listed explicitly
The question in the title: What we do not know about retatrutide, listed explicitly I will give what I have already checked below so nobody repeats it. Setting out what I think I know about this compound and…
|
+106 | 113 | 4.8k | 17mo |
|
Pooling trials with different estimands — what changed since
Pooling trials with different estimands — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Pooling trials with different…
|
+57 | 64 | 12k | 7mo |